Insider Transactions in Q3 2023 at Apellis Pharmaceuticals, Inc. (APLS)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2023
|
Cedric Francois Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
150,000
+15.72%
|
-
|
|
Sep 19
2023
|
Cedric Francois Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
150,000
-35.32%
|
-
|
|
Sep 18
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.34%
|
$56,250
$45.0 P/Share
|
|
Sep 18
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.34%
|
$2,500
$2.67 P/Share
|
|
Sep 18
2023
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
20,350
-14.92%
|
$895,400
$44.18 P/Share
|
|
Sep 18
2023
|
Nur Nicholson Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,719
+11.66%
|
$281,851
$29.76 P/Share
|
|
Sep 15
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.34%
|
$56,250
$45.34 P/Share
|
|
Sep 15
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.34%
|
$2,500
$2.67 P/Share
|
|
Sep 14
2023
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+7.08%
|
-
|
|
Sep 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.12%
|
$504,000
$42.87 P/Share
|
|
Sep 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.7%
|
$37,000
$2.67 P/Share
|
|
Sep 06
2023
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,756
-2.51%
|
$75,508
$43.01 P/Share
|
|
Sep 01
2023
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
150,000
-13.34%
|
$6,300,000
$42.07 P/Share
|
|
Sep 01
2023
|
Cedric Francois Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+34.3%
|
$600,000
$2.67 P/Share
|
|
Aug 31
2023
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
551
-1.79%
|
$22,591
$41.23 P/Share
|
|
Aug 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.13%
|
$276,000
$23.66 P/Share
|
|
Aug 08
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.71%
|
$37,000
$2.67 P/Share
|
|
Jul 21
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
49,779
+11.93%
|
$99,558
$2.67 P/Share
|
|
Jul 20
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+13.6%
|
$100,000
$2.67 P/Share
|
|
Jul 17
2023
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.46%
|
$80,000
$64.79 P/Share
|
|
Jul 17
2023
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.46%
|
$2,500
$2.67 P/Share
|
|
Jul 10
2023
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.13%
|
$1,008,000
$84.55 P/Share
|
|
Jul 10
2023
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.72%
|
$37,000
$2.67 P/Share
|
|
Jul 03
2023
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
8,510
-9.03%
|
$757,390
$89.98 P/Share
|
|
Jul 03
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,779
-2.74%
|
$610,110
$90.31 P/Share
|
|
Jul 03
2023
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,779
+7.43%
|
$67,790
$10.03 P/Share
|